vs

Side-by-side financial comparison of American Express (AXP) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $18.9M, roughly 1.2× American Express). American Express runs the higher net margin — 15.7% vs -165.4%, a 181.2% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs -25.3%). Over the past eight quarters, NEKTAR THERAPEUTICS's revenue compounded faster (0.4% CAGR vs -95.6%).

American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

AXP vs NKTR — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.2× larger
NKTR
$21.8M
$18.9M
AXP
Growing faster (revenue YoY)
AXP
AXP
+36.7% gap
AXP
11.4%
-25.3%
NKTR
Higher net margin
AXP
AXP
181.2% more per $
AXP
15.7%
-165.4%
NKTR
Faster 2-yr revenue CAGR
NKTR
NKTR
Annualised
NKTR
0.4%
-95.6%
AXP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AXP
AXP
NKTR
NKTR
Revenue
$18.9M
$21.8M
Net Profit
$3.0M
$-36.1M
Gross Margin
Operating Margin
-126.9%
Net Margin
15.7%
-165.4%
Revenue YoY
11.4%
-25.3%
Net Profit YoY
15.0%
-596.9%
EPS (diluted)
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXP
AXP
NKTR
NKTR
Q1 26
$18.9M
Q4 25
$10.9B
$21.8M
Q3 25
$10.4B
$11.8M
Q2 25
$10.3B
$11.2M
Q1 25
$9.6B
$10.5M
Q4 24
$10.0B
$29.2M
Q3 24
$9.7B
$24.1M
Q2 24
$9.8B
$23.5M
Net Profit
AXP
AXP
NKTR
NKTR
Q1 26
$3.0M
Q4 25
$2.5B
$-36.1M
Q3 25
$2.9B
$-35.5M
Q2 25
$2.9B
$-41.6M
Q1 25
$2.6B
$-50.9M
Q4 24
$2.2B
$7.3M
Q3 24
$2.5B
$-37.1M
Q2 24
$3.0B
$-52.4M
Gross Margin
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Operating Margin
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
28.2%
-126.9%
Q3 25
36.7%
-268.6%
Q2 25
34.4%
-324.2%
Q1 25
34.6%
-425.8%
Q4 24
27.7%
49.2%
Q3 24
33.0%
-142.4%
Q2 24
38.6%
-211.9%
Net Margin
AXP
AXP
NKTR
NKTR
Q1 26
15.7%
Q4 25
22.5%
-165.4%
Q3 25
27.9%
-301.3%
Q2 25
28.0%
-372.2%
Q1 25
26.8%
-486.4%
Q4 24
21.8%
24.9%
Q3 24
25.8%
-153.6%
Q2 24
30.7%
-222.9%
EPS (diluted)
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
$3.52
$-4.67
Q3 25
$4.14
$-1.87
Q2 25
$4.08
$-2.95
Q1 25
$3.64
$-0.24
Q4 24
$3.04
$-2.07
Q3 24
$3.49
$-2.66
Q2 24
$4.15
$-3.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXP
AXP
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
$60.4M
Stockholders' EquityBook value
$34.0M
$89.8M
Total Assets
$308.9M
$280.4M
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
$742.0M
$15.1M
Q3 25
$1.3B
$41.0M
Q2 25
$197.0M
$43.0M
Q1 25
$261.0M
$38.9M
Q4 24
$221.0M
$44.3M
Q3 24
$120.0M
$30.1M
Q2 24
$188.0M
$27.9M
Total Debt
AXP
AXP
NKTR
NKTR
Q1 26
$60.4M
Q4 25
$56.4B
Q3 25
$57.8B
Q2 25
$58.2B
Q1 25
$51.2B
Q4 24
$49.7B
Q3 24
$53.5B
Q2 24
$51.5B
Stockholders' Equity
AXP
AXP
NKTR
NKTR
Q1 26
$34.0M
Q4 25
$33.5B
$89.8M
Q3 25
$32.4B
$85.1M
Q2 25
$32.3B
$-24.2M
Q1 25
$31.2B
$13.7M
Q4 24
$30.3B
$60.7M
Q3 24
$29.7B
$48.9M
Q2 24
$29.5B
$79.7M
Total Assets
AXP
AXP
NKTR
NKTR
Q1 26
$308.9M
Q4 25
$300.1B
$280.4M
Q3 25
$297.6B
$301.3M
Q2 25
$295.6B
$207.5M
Q1 25
$282.2B
$256.2M
Q4 24
$271.5B
$303.9M
Q3 24
$271.0B
$308.0M
Q2 24
$272.2B
$343.3M
Debt / Equity
AXP
AXP
NKTR
NKTR
Q1 26
1.78×
Q4 25
1.68×
Q3 25
1.78×
Q2 25
1.80×
Q1 25
1.64×
Q4 24
1.64×
Q3 24
1.80×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXP
AXP
NKTR
NKTR
Operating Cash FlowLast quarter
$-65.0M
Free Cash FlowOCF − Capex
$-65.0M
FCF MarginFCF / Revenue
-298.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
$3.1B
$-65.0M
Q3 25
$6.2B
$-48.8M
Q2 25
$4.4B
$-45.7M
Q1 25
$4.8B
$-49.1M
Q4 24
$5.8B
$-46.2M
Q3 24
$-1.8B
$-43.9M
Q2 24
$4.5B
$-37.7M
Free Cash Flow
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
$2.3B
$-65.0M
Q3 25
$5.6B
$-48.9M
Q2 25
$3.7B
$-45.8M
Q1 25
$4.3B
$-49.1M
Q4 24
$5.3B
$-46.6M
Q3 24
$-2.3B
$-44.6M
Q2 24
$4.0B
$-37.9M
FCF Margin
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
21.4%
-298.0%
Q3 25
53.6%
-414.5%
Q2 25
36.3%
-409.6%
Q1 25
45.0%
-469.0%
Q4 24
53.1%
-159.9%
Q3 24
-23.3%
-184.9%
Q2 24
40.4%
-161.3%
Capex Intensity
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
6.6%
0.1%
Q3 25
6.3%
1.0%
Q2 25
6.0%
0.3%
Q1 25
4.5%
0.0%
Q4 24
5.0%
1.6%
Q3 24
4.7%
2.8%
Q2 24
5.8%
0.8%
Cash Conversion
AXP
AXP
NKTR
NKTR
Q1 26
Q4 25
1.25×
Q3 25
2.15×
Q2 25
1.51×
Q1 25
1.84×
Q4 24
2.66×
-6.36×
Q3 24
-0.72×
Q2 24
1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXP
AXP

Discount revenue$9.5M50%
Other$8.9M47%
Deposits with banks and other$512.0K3%

NKTR
NKTR

Segment breakdown not available.

Related Comparisons